Supplementary Table 1: Expanded baseline characteristics of randomized participants

	China	Europe	All
Number randomized	10932	14741	25673
Age (years)			
Mean (SD)	63.4 (7.6)	65.9 (7.2)	64.9 (7.5)
<65	6216 (56.9%)	6716 (45.6%)	12932 (50.4%)
≥65 <70	2160 (19.8%)	3464 (23.5%)	5624 (21.9%)
≥70	2556 (23.4%)	4561 (30.9%)	7117 (27.7%)
Sex			
Male	8680 (79.4%)	12549 (85.1%)	21229 (82.7%)
Female	2252 (20.6%)	2192 (14.9%)	4444 (17.3%)
History			
Coronary disease			
Myocardial infarction	6999 (64.0%)	10346 (70.2%)	17345 (67.6%)
Angina	3950 (36.1%)	3967 (26.9%)	7917 (30.8%)
Coronary revascularization	5411 (49.5%)	8517 (57.8%)	13928 (54.3%)
Any coronary disease	8407 (76.9%)	11730 (79.6%)	20137 (78.4%)
Cerebrovascular disease			
Presumed ischaemic stroke	4207 (38.5%)	2364 (16.0%)	6571 (25.6%)
Haemorrhagic stroke	189 (1.7%)	153 (1.0%)	342 (1.3%)
Transient ischaemic attack	342 (3.1%)	1458 (9.9%)	1800 (7.0%)
Cerebral revascularization	41 (0.4%)	545 (3.7%)	586 (2.3%)
Any cerebrovascular disease	4462 (40.8%)	3708 (25.2%)	8170 (31.8%)
Peripheral arterial disease			
Intermittent claudication	464 (4.2%)	2216 (15.0%)	2680 (10.4%)
Peripheral revascularization	85 (0.8%)	1465 (9.9%)	1550 (6.0%)
Any peripheral arterial disease	508 (4.6%)	2706 (18.4%)	3214 (12.5%)
Glycaemic status[a]			
Abnormal glucose tolerance	1152 (10.5%)	1010 (6.9%)	2162 (8.4%)
Diabetes mellitus	4611 (42.2%)	3688 (25.0%)	8299 (32.3%)
Metabolic syndrome[b]	4149 (38.0%)	5167 (35.1%)	9316 (36.3%)
Treated hypertension	6894 (63.1%)	9025 (61.2%)	15919 (62.0%)
Heart Failure[c]			
NYHA 1-2	434 (4.0%)	931 (6.3%)	1365 (5.3%)
NYHA 3-4	38 (0.3%)	28 (0.2%)	66 (0.3%)
Smoking status			
Never	4197 (38.4%)	4529 (30.7%)	8726 (34.0%)
Former	4248 (38.9%)	8089 (54.9%)	12337 (48.1%)
Current	2487 (22.7%)	2123 (14.4%)	4610 (18.0%)
Alcohol intake (units/week)			
None	9516 (87.0%)	5669 (38.5%)	15185 (59.1%)
>0 <21	1243 (11.4%)	7780 (52.8%)	9023 (35.1%)
≥21	173 (1.6%)	1292 (8.8%)	1465 (5.7%)

[a] Abnormal glucose tolerance: Not diabetic and baseline plasma glucose ≥7.8 mmol/l if fasted <8 hours or ≥6.0 mmol/l if fasted ≥8 hours); Diabetes (self-reported, or baseline plasma glucose ≥11.1 mmol/l if fasted <8 hours or ≥7.0 mmol/l if fasted ≥8 hours, or baseline HbA1c≥48 mmol/mol, or use of hypoglycaemic medication at randomization)
[b] As defined by ATP III
[c] New York Heart Association grade (NYHA) grade
[d] Waist circumference: Normal (men <94, women <80); Increased (men ≥94 <102, women ≥80 <88); Excessive (men ≥102, women ≥88)
[e] Angiotensin converting enzyme inhibitor (ACEi) or angiotensin-2 receptor blocker (ARB)

Supplementary Table 1: Expanded baseline characteristics of randomized participants

	China	Europe	All
Physical measurements			
Systolic blood pressure (mmHg)			
<140	5109 (46.7%)	6342 (43.0%)	11451 (44.6%)
≥140 <160	3447 (31.5%)	5244 (35.6%)	8691 (33.9%)
≥160	2376 (21.7%)	3155 (21.4%)	5531 (21.5%)
Diastolic blood pressure (mmHg)			
<90	8599 (78.7%)	11546 (78.3%)	20145 (78.5%)
≥90 <100	1651 (15.1%)	2522 (17.1%)	4173 (16.3%)
≥100	682 (6.2%)	673 (4.6%)	1355 (5.3%)
Body mass index (kg/m^2)			
<25	3901 (35.7%)	2701 (18.3%)	6602 (25.7%)
≥25 <30	5865 (53.6%)	6995 (47.5%)	12860 (50.1%)
≥30	1166 (10.7%)	5045 (34.2%)	6211 (24.2%)
Waist circumference (cm)[d]			
Normal	4888 (44.7%)	2855 (19.4%)	7743 (30.2%)
Increased	3368 (30.8%)	3958 (26.9%)	7326 (28.5%)
Excessive	2676 (24.5%)	7928 (53.8%)	10604 (41.3%)
Medications			
Current statin use (years)			
None	5625 (51.5%)	566 (3.8%)	6191 (24.1%)
>0 <3	4339 (39.7%)	3811 (25.9%)	8150 (31.7%)
≥3 <6	750 (6.9%)	4584 (31.1%)	5334 (20.8%)
≥6	218 (2.0%)	5780 (39.2%)	5998 (23.4%)
Study LDL-lowering therapy (daily)			
Simvastatin 40 mg	8051 (73.6%)	5491 (37.2%)	13542 (52.7%)
Ezetimibe/simvastatin 10/40 mg	2881 (26.4%)	9250 (62.8%)	12131 (47.3%)
Non-study medications			
Aspirin	9417 (86.1%)	12742 (86.4%)	22159 (86.3%)
Other antiplatelet	1910 (17.5%)	2727 (18.5%)	4637 (18.1%)
ACEi or ARB[e]	4657 (42.6%)	10090 (68.4%)	14747 (57.4%)
Diuretic	969 (8.9%)	3750 (25.4%)	4719 (18.4%)
Calcium channel blocker	3454 (31.6%)	3638 (24.7%)	7092 (27.6%)
Beta blocker	5635 (51.5%)	9495 (64.4%)	15130 (58.9%)

[a] Abnormal glucose tolerance: Not diabetic and baseline plasma glucose ≥7.8 mmol/l if fasted <8 hours or ≥6.0 mmol/l if fasted ≥8 hours); Diabetes (self-reported, or baseline plasma glucose ≥11.1 mmol/l if fasted <8 hours or ≥7.0 mmol/l if fasted ≥8 hours, or baseline HbA1c≥48 mmol/mol, or use of hypoglycaemic medication at randomization)
[b] As defined by ATP III
[c] New York Heart Association grade (NYHA) grade
[d] Waist circumference: Normal (men <94, women <80); Increased (men ≥94 <102, women ≥80 <88); Excessive (men ≥102, women ≥88)
[e] Angiotensin converting enzyme inhibitor (ACEi) or angiotensin-2 receptor blocker (ARB)

Supplementary Table 2: Baseline lipids and other biochemical characteristics of randomized participants

	China	Europe	All
Number randomized	10932	14741	25673
Baseline lipids[a]			
Total Cholesterol (mmol/l)			
Mean (SD)	3.14 (0.54)	3.45 (0.55)	3.32 (0.57)
<3.0	4308 (39.4%)	2821 (19.1%)	7129 (27.8%)
≥3.0 <3.5	4044 (37.0%)	5447 (37.0%)	9491 (37.0%)
≥3.5	2580 (23.6%)	6473 (43.9%)	9053 (35.3%)
LDL-C (mmol/l)			
Mean (SD)	1.51 (0.41)	1.74 (0.43)	1.64 (0.44)
<1.5	5579 (51.0%)	4281 (29.0%)	9860 (38.4%)
≥1.5 <2.0	4278 (39.1%)	6776 (46.0%)	11054 (43.1%)
≥2.0	1075 (9.8%)	3684 (25.0%)	4759 (18.5%)
ApoB (g/l)			
Mean (SD)	0.65 (0.13)	0.70 (0.14)	0.68 (0.14)
<0.6	4116 (37.7%)	3174 (21.5%)	7290 (28.4%)
≥0.6 <0.7	3330 (30.5%)	4961 (33.7%)	8291 (32.3%)
≥0.7	3486 (31.9%)	6606 (44.8%)	10092 (39.3%)
HDL-C (mmol/l)			
Mean (SD)	1.06 (0.24)	1.19 (0.31)	1.14 (0.29)
<0.9	2616 (23.9%)	2284 (15.5%)	4900 (19.1%)
≥0.9 <1.1	4056 (37.1%)	4079 (27.7%)	8135 (31.7%)
≥1.1	4260 (39.0%)	8378 (56.8%)	12638 (49.2%)
ApoA1 (g/l)			
Mean (SD)	1.38 (0.21)	1.51 (0.24)	1.45 (0.24)
<1.4	6340 (58.0%)	4896 (33.2%)	11236 (43.8%)
≥1.4 <1.6	3102 (28.4%)	5311 (36.0%)	8413 (32.8%)
≥1.6	1490 (13.6%)	4534 (30.8%)	6024 (23.5%)
Triglycerides (mmol/l)			
Mean (SD)	1.40 (0.81)	1.46 (0.86)	1.43 (0.84)
Median (IQR)	1.20 (0.75)	1.24 (0.86)	1.22 (0.82)
<1.0	3574 (32.7%)	4723 (32.0%)	8297 (32.3%)
≥1.0 <1.7	4802 (43.9%)	5999 (40.7%)	10801 (42.1%)
≥1.7	2556 (23.4%)	4019 (27.3%)	6575 (25.6%)
Renal			
eGFR (ml/min/1.73m^2)[b]			
<60	1022 (9.3%)	2501 (17.0%)	3523 (13.7%)
≥60	9910 (90.7%)	12240 (83.0%)	22150 (86.3%)
Urine ACR (mg/mmol)[c]			
<3.4	9063 (82.9%)	13108 (88.9%)	22171 (86.4%)
≥3.4 <34	1564 (14.3%)	1423 (9.7%)	2987 (11.6%)
≥34	305 (2.8%)	210 (1.4%)	515 (2.0%)

[a] 97% of participants had all baseline lipid measurements available.
[b] Estimated glomerular filtration rate (eGFR) calculated by CKD-EPI formula (see methods)
[c] Albumin:creatinine ratio (ACR)
For categorical analyses, participants with missing values were assigned to the median value group

Supplementary Table 2: Baseline lipids and other biochemical characteristics of randomized participants

	China	Europe	All
HbA1c (mmol/mol)			
Participants with diabetes mellitus			
<53	3320 (72.0%)	2532 (68.7%)	5852 (70.5%)
≥53	1291 (28.0%)	1156 (31.3%)	2447 (29.5%)
All participants			
<37	6060 (55.4%)	7419 (50.3%)	13479 (52.5%)
≥37 <48	2975 (27.2%)	5539 (37.6%)	8514 (33.2%)
≥48	1897 (17.4%)	1783 (12.1%)	3680 (14.3%)

[a] 97% of participants had all baseline lipid measurements available.
[b] Estimated glomerular filtration rate (eGFR) calculated by CKD-EPI formula (see methods)
[c] Albumin:creatinine ratio (ACR)
For categorical analyses, participants with missing values were assigned to the median value group

Supplementary Table 3: Reasons for stopping randomized treatment by region

	ERN/LRPT	Placebo	Excess[a] (SE)
Number randomized			
China	5464	5468	
Europe	7374	7367	
Medical reasons			
Any skin reason			
China	221 (4.0%)	57 (1.0%)	3.0% (0.3%)
Europe	476 (6.5%)	103 (1.4%)	5.1% (0.3%)
Any gastrointestinal reason			
China	189 (3.5%)	91 (1.7%)	1.8% (0.3%)
Europe	306 (4.1%)	128 (1.7%)	2.4% (0.3%)
Any hepatobiliary reason			
China	35 (0.6%)	24 (0.4%)	0.2% (0.1%)
Europe	17 (0.2%)	19 (0.3%)	-0.0% (0.1%)
Any musculoskeletal reason			
China	101 (1.8%)	29 (0.5%)	1.3% (0.2%)
Europe	124 (1.7%)	99 (1.3%)	0.3% (0.2%)
Any diabetes-related reason			
China	63 (1.2%)	17 (0.3%)	0.8% (0.2%)
Europe	56 (0.8%)	33 (0.4%)	0.3% (0.1%)
Any other medical reason			
China	167 (3.1%)	133 (2.4%)	0.6% (0.3%)
Europe	353 (4.8%)	288 (3.9%)	0.9% (0.3%)
Any medical reason			
China	775 (14.2%)	350 (6.4%)	7.8% (0.6%)
Europe	1332 (18.1%)	670 (9.1%)	9.0% (0.6%)
Non-medical reasons			
China	431 (7.9%)	326 (6.0%)	1.9% (0.5%)
Europe	718 (9.7%)	790 (10.7%)	-1.0% (0.5%)
Any reason for stopping			
China	1206 (22.1%)	676 (12.4%)	9.7% (0.7%)
Europe	2050 (27.8%)	1460 (19.8%)	8.0% (0.7%)

[a] Excess is defined as the absolute percentage of patients who had the event in the ERN/LRPT group minus the percentage who had the event in the placebo group

Supplementary Table 4: Liver and muscle-related events during follow-up in China

	ERN/LRPT	Placebo
Number randomized	5464	5468
Person years follow-up	21063	21203
Abnormal alanine transaminase (ALT)		
Results collected at routine visits		
>3 ≤5x ULN	79 (0.38%/y)	24 (0.11%/y)
>5 ≤10x ULN	15 (0.07%/y)	5 (0.02%/y)
>10x ULN	2 (<0.01%/y)	4 (0.02%/y)
Any >3 x ULN	96 (0.46%/y)	33 (0.16%/y)
Any >3 x ULN without muscle damage[a]	80 (0.38%/y)	32 (0.15%/y)
>3x ULN + bilirubin ≥2x ULN	1 (<0.01%/y)	1 (<0.01%/y)
All results[b]		
>3 ≤5x ULN	139 (0.66%/y)	45 (0.21%/y)
>5 ≤10x ULN	65 (0.31%/y)	23 (0.11%/y)
>10x ULN	31 (0.15%/y)	16 (0.08%/y)
Any >3 x ULN	235 (1.12%/y)	84 (0.40%/y)
Any >3 x ULN without muscle damage[a]	158 (0.75%/y)	72 (0.34%/y)
Consecutive >3x ULN	71 (0.34%/y)	22 (0.10%/y)
Consecutive >3x ULN without muscle damage[a]	31 (0.15%/y)	18 (0.08%/y)
>3x ULN + bilirubin ≥2x ULN	8 (0.04%/y)	12 (0.06%/y)
Myopathy		
Definite myopathy		
Rhabdomyolysis	5 (0.02%/y)	1 (<0.01%/y)
Any definite myopathy	68 (0.32%/y)	13 (0.06%/y)
Incipient myopathy[c]		
Symptomatic	18 (0.09%/y)	8 (0.04%/y)
Asymptomatic	54 (0.26%/y)	7 (0.03%/y)
Any incipient myopathy	71 (0.34%/y)	14 (0.07%/y)
Any myopathy	138 (0.66%/y)	27 (0.13%/y)

[a] Muscle damage defined as simultaneous creatine kinase >5x baseline and >3x ULN (within 7 days) of the ALT abnormality or diagnosis of myopathy (within 28 days)
[b] Includes results collected at routine and recall visits as well as external reports
[c] Incipient myopathy with no definite myopathy within 28 days

Supplementary Table 5: Liver and muscle-related events during follow-up in Europe

	ERN/LRPT	Placebo
Number randomized	7374	7367
Person years follow-up	25176	25156
Abnormal alanine transaminase (ALT)		
Results collected at routine visits		
>3 ≤5x ULN	32 (0.13%/y)	23 (0.09%/y)
>5 ≤10x ULN	8 (0.03%/y)	10 (0.04%/y)
>10x ULN	4 (0.02%/y)	1 (<0.01%/y)
Any >3 x ULN	44 (0.17%/y)	34 (0.14%/y)
Any >3 x ULN without muscle damage[a]	44 (0.17%/y)	33 (0.13%/y)
>3x ULN + bilirubin ≥2x ULN	2 (<0.01%/y)	4 (0.02%/y)
All results[b]		
>3 ≤5x ULN	51 (0.20%/y)	31 (0.12%/y)
>5 ≤10x ULN	16 (0.06%/y)	12 (0.05%/y)
>10x ULN	13 (0.05%/y)	6 (0.02%/y)
Any >3 x ULN	80 (0.32%/y)	49 (0.19%/y)
Any >3 x ULN without muscle damage[a]	76 (0.30%/y)	47 (0.19%/y)
Consecutive >3x ULN	17 (0.07%/y)	12 (0.05%/y)
Consecutive >3x ULN without muscle damage[a]	17 (0.07%/y)	12 (0.05%/y)
>3x ULN + bilirubin ≥2x ULN	6 (0.02%/y)	6 (0.02%/y)
Myopathy		
Definite myopathy		
Rhabdomyolysis	2 (<0.01%/y)	4 (0.02%/y)
Any definite myopathy	7 (0.03%/y)	4 (0.02%/y)
Incipient myopathy[c]		
Symptomatic	5 (0.02%/y)	4 (0.02%/y)
Asymptomatic	5 (0.02%/y)	3 (0.01%/y)
Any incipient myopathy	10 (0.04%/y)	7 (0.03%/y)
Any myopathy	17 (0.07%/y)	11 (0.04%/y)

[a] Muscle damage defined as simultaneous creatine kinase >5x baseline and >3x ULN (within 7 days) of the ALT abnormality or diagnosis of myopathy (within 28 days)
[b] Includes results collected at routine and recall visits as well as external reports
[c] Incipient myopathy with no definite myopathy within 28 days